Medicus Pharma Ltd (NASDAQ:MDCX) Sees Significant Growth in Short Interest

Medicus Pharma Ltd (NASDAQ:MDCX) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 775,343 shares, a growth of 57.1% from the November 30th total of 493,429 shares. Based on an average daily volume of 422,422 shares, the days-to-cover ratio is currently 1.8 days. Approximately 4.0% of the company’s shares are short sold. Approximately 4.0% of the company’s shares are short sold. Based on an average daily volume of 422,422 shares, the days-to-cover ratio is currently 1.8 days.

Analyst Upgrades and Downgrades

MDCX has been the topic of several recent analyst reports. Zacks Research upgraded Medicus Pharma to a “hold” rating in a research report on Monday, September 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 22nd. Finally, D. Boral Capital reissued a “buy” rating and issued a $27.00 target price on shares of Medicus Pharma in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medicus Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Medicus Pharma during the 2nd quarter worth approximately $41,000. Osaic Holdings Inc. grew its holdings in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares in the last quarter. Brave Asset Management Inc. acquired a new stake in shares of Medicus Pharma in the 3rd quarter valued at about $46,000. Wilmington Savings Fund Society FSB bought a new position in shares of Medicus Pharma during the third quarter worth about $59,000. Finally, May Hill Capital LLC bought a new stake in Medicus Pharma in the second quarter valued at about $107,000.

Medicus Pharma Trading Up 6.5%

MDCX traded up $0.10 during trading on Tuesday, hitting $1.56. 378,681 shares of the company’s stock were exchanged, compared to its average volume of 271,653. The stock has a 50 day moving average price of $2.07 and a 200 day moving average price of $2.36. Medicus Pharma has a 1 year low of $1.45 and a 1 year high of $8.94. The firm has a market cap of $34.26 million and a P/E ratio of -0.72.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). Analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.